Recent Price Movement and Market Context
On 9 January 2026, TTK Healthcare Ltd. closed near its 52-week low, marking a significant milestone in its recent trading trajectory. The stock has declined by 1.53% over the past two consecutive sessions, aligning with the sector's overall performance. The day’s trading saw a modest dip of 0.89%, with the stock trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning indicates sustained downward momentum over multiple time horizons.
The broader market environment also reflected cautious sentiment. The Nifty index closed at 25,683.30, down 193.55 points or 0.75%, and remains 2.69% below its 52-week high of 26,373.20. Notably, all market capitalisation segments experienced declines, with the Nifty Small Cap 100 index falling by 1.81%, exerting additional pressure on smaller and mid-sized stocks.
Long-Term Performance and Comparative Analysis
TTK Healthcare’s one-year performance stands at -26.68%, significantly underperforming the Sensex, which posted a positive return of 7.67% over the same period. The stock’s 52-week high was Rs 1,398.90, underscoring the extent of the recent decline. Over the last three years, the stock has consistently lagged behind the BSE500 index, reflecting persistent challenges in generating shareholder value relative to the broader market.
Despite operating within the diversified sector, the company’s market capitalisation grade is rated at 3, indicating a mid-tier valuation relative to peers. The Mojo Score of 37.0 and a recent downgrade from Hold to Sell on 21 July 2025 further highlight the cautious stance adopted by rating agencies.
Our latest monthly pick, this Large Cap from Aluminium & Aluminium Products, is outperforming the market! See the analysis that helped our Investment Committee select this winner.
- - Market-beating performance
- - Committee-backed winner
- - Aluminium & Aluminium Products standout
Financial Metrics and Profitability Trends
TTK Healthcare’s financial results have exhibited limited growth over recent years. Net sales have increased at an annualised rate of 7.36% over the past five years, a modest pace relative to industry standards. The company reported a Profit Before Tax (PBT) of Rs 2.29 crore in the September 2025 quarter, representing a sharp decline of 58.29% compared to the previous period. Notably, non-operating income accounted for 89.25% of the PBT, indicating a significant reliance on income sources outside core business activities.
Return on Equity (ROE) stands at 6.5%, which, while positive, is moderate for a company of this size and sector. The Price to Book Value ratio is 1.3, suggesting an attractive valuation on a book value basis. However, the Price/Earnings to Growth (PEG) ratio of 2.2 points to a valuation premium relative to the company’s earnings growth rate, which has been 9.3% over the past year despite the stock’s negative return.
Shareholding and Market Sentiment
Domestic mutual funds hold a minimal stake of just 0.01% in TTK Healthcare Ltd., a figure that may reflect limited institutional conviction. Given the capacity of mutual funds to conduct detailed research and due diligence, this small holding could indicate a cautious approach towards the stock’s current valuation and business prospects.
The company maintains a low average debt-to-equity ratio of zero, underscoring a conservative capital structure with limited leverage. This financial prudence, however, has not translated into stronger market performance or investor confidence in recent periods.
Why settle for TTK Healthcare Ltd.? SwitchER evaluates this Diversified small-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Technical and Sectoral Considerations
Technically, the stock’s position below all major moving averages signals a bearish trend that has persisted over multiple time frames. This technical weakness is compounded by the broader sector’s subdued performance, with the diversified sector mirroring the market’s cautious tone. The Nifty’s 50-day moving average remains below its 200-day moving average, a configuration often interpreted as a sign of market consolidation or correction phases.
TTK Healthcare’s relative underperformance compared to sector peers and market indices highlights the challenges faced in regaining momentum. The stock’s premium valuation relative to historical peer averages suggests that market participants may be pricing in expectations that have yet to materialise in earnings or sales growth.
Summary of Key Data Points
To summarise, TTK Healthcare Ltd. has experienced a notable decline to near its 52-week low of Rs 991, closing just 0.8% above this level. The stock’s one-year return of -26.68% contrasts sharply with the Sensex’s positive 7.67% return. Financially, the company’s sales growth remains modest at 7.36% annually over five years, with recent quarterly PBT falling by over 58%. The company’s conservative debt profile and moderate ROE of 6.5% are positive attributes, yet these have not translated into stronger market performance. Institutional interest remains limited, with domestic mutual funds holding a negligible stake.
Overall, the stock’s current valuation and technical indicators reflect a period of subdued investor confidence and market caution.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
